Skip to main content
Clinical Trials/ISRCTN50181543
ISRCTN50181543
Completed
N/A

Phase II trial: Pre-operative, long-term chemoradiation with capecitabine, oxaliplatin and bevacizumab in locally advanced rectal cancer

niversity Medical Centre Schleswig-Holstein (Universitätsklinikum Schleswig-Holstein) (Germany)0 sites68 target enrollmentMay 9, 2008

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity Medical Centre Schleswig-Holstein (Universitätsklinikum Schleswig-Holstein) (Germany)
Enrollment
68
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 9, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity Medical Centre Schleswig-Holstein (Universitätsklinikum Schleswig-Holstein) (Germany)

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \>18 years, both males and females
  • 2\. Patients with histologically proven adenocarcinoma of the rectum, tumour \= 16 cm from the anal verge, u T3\-4 or uN\+ or Mason III/IV, staging will must be done by endorectal ultrasound and magnetic resonance imaging (MRI) or by endorectal unltrasound and high resolution computed tomography, no evidence of metastatic disease
  • 3\. No prior treatment, except for ileostomy (if necessary due to ileus)
  • 4\. No fistulas near the tumour
  • 5\. Eastern Cooperative Oncology Group (ECOG) Performance Status \<\= 1
  • 6\. Adequate bone marrow, hepatic and renal function:
  • 6\.1\. Haemoglobin \>10\.0 g/dL, leucocyte count \> 3\.5 x 109/L, absolute neutrophil count \>1\.5 x 109/L, platelet count \>100 x 109/L
  • 6\.2\. Alkaline phosphatase, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) \<3 x upper limit of normal (ULN)
  • 6\.3\. Total bilirubin \<\= 2 mg/dL
  • 6\.4\. Creatinine clearance \>50 mL/min

Exclusion Criteria

  • 1\. No presence of adequate contraception in fertile patients
  • 2\. Pregnant or breastfeeding women
  • 3\. Previous or persistent alcohol or drug abuses
  • 4\. Prior radiotherapy or chemotherapy to the pelvis, for any reason
  • 5\. Treatment with any investigational drug, agent nor procedure, (i.e. did not participate in another trial) within 4 weeks before entry in this trial
  • 6\. Treatment with other anti\-cancer agents
  • 7\. Patients not able or willing to comply with the protocol treatment and investigations
  • 8\. Patients with uncontrolled severe somatic or psychological diseases, e.g.:
  • 8\.1\. Despite medication uncontrolled cardiac diseases, myocardial infarction within the last 6 months prior to enrolment
  • 8\.2\. Neurological or psychiatric disorders including seizures and dementia

Outcomes

Primary Outcomes

Not specified

Similar Trials